Nuvalent, Inc. (NUVL)
$123.96+0.00%Close
BUYBULL · day 29
Key stats
- Market cap
- $9.1B
- Beta
- 1.14
- P/E (TTM)
- -20.46
- 1W
- +0.00%
- 1M
- +0.43%
- vs SPY 1W
- +0.98%
- vs SPY 1M
- -1.44%
Industry peers
FMP comparable companies · ranked by market cap
- JAZZSELLJazz Pharmaceuticals plc$13.7BBEARQ 24$218.42-0.35%
- PCVXBUYVaxcyte, Inc.$10.3BRECOVERYQ 25$71.38+1.12%
- ARWRSELLArrowhead Pharmaceuticals, Inc.$8.8BCRISISQ 12$62.75+0.41%
- AXSMSELLAxsome Therapeutics, Inc.$8.7BCRISISQ 34$168.35+3.77%
- CYTKSELLCytokinetics, Incorporated$7.8BRECOVERYQ 9$62.91+2.94%
- MTSRMetsera, Inc.$7.4B$70.50
- MRUSMerus N.V.$6.8B$90.00
- ABVXSELLAbivax S.A.$6.5BCRISISQ 57$88.15+2.04%
- RYTMSELLRhythm Pharmaceuticals, Inc.$6.2BBEARQ 20$90.78+0.12%
- CRSPSELLCRISPR Therapeutics AG$5.1BCRISISQ 20$53.39+0.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NUVL?
- LOPJLB’s latest quantitative signal on Nuvalent, Inc. (NUVL) is BUY in a BULL regime. Signals are updated daily.
- What market regime is NUVL in?
- Nuvalent, Inc. (NUVL) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Nuvalent, Inc. (NUVL) do?
- Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase …